Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group - Archive ouverte HAL Access content directly
Journal Articles American Journal of Hematology Year : 2017

Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group

, , , (1) , (2) , (3) , (4) , (5) , (6) , (7) , , (8) , (9) , (10) , (11) , (12)
1
2
3
4
5
6
7
8
9
10
11
12

Domains

Life Sciences [q-bio] Human health and pathology Hematology

DOMINIQUE CHADEYRON  : Connect in order to contact the contributor

https://hal.uca.fr/hal-01653723

Submitted on : Friday, December 1, 2017-6:06:12 PM

Last modification on : Monday, November 28, 2022-10:38:07 AM

Consult the full text

Dates and versions

hal-01653723 , version 1 (01-12-2017)

Identifiers

Cite

Sophie Michallet, Arnaud Campidelli, Helene Lequeu, Marie-Sarah Dilhuydy, Olivier Tournilhac, et al.. Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group. American Journal of Hematology, 2017, 92 (6), pp.E105 - E107. ⟨10.1002/ajh.24715⟩. ⟨hal-01653723⟩

Export

BibTeX TEI Dublin Core DC Terms EndNote Datacite

Collections

UNIV-PARIS13 UNIV-RENNES1 PRES_CLERMONT CNRS INRIA UNIV-LYON1 FNCLCC IGR UPEC BIOENVIS USPC UNIV-PARIS-SACLAY ASIH CHELTER UNIV-RENNES SORBONNE-UNIVERSITE SU-MEDECINE UDL SORBONNE-PARIS-NORD UNIV-UT3 UT3-TOULOUSEINP
216 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More